Game Creek Capital LP Invests $1.79 Million in Eli Lilly and Company $LLY

Game Creek Capital LP purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 2,300 shares of the company’s stock, valued at approximately $1,793,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Brighton Jones LLC lifted its stake in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the last quarter. Kaufman Rossin Wealth LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at about $242,000. Horizon Investments LLC lifted its stake in Eli Lilly and Company by 6.3% in the 1st quarter. Horizon Investments LLC now owns 9,491 shares of the company’s stock worth $7,839,000 after purchasing an additional 559 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Eli Lilly and Company by 2.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,796,285 shares of the company’s stock worth $3,135,290,000 after purchasing an additional 94,078 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,027.68 on Friday. The stock has a market cap of $971.55 billion, a PE ratio of 50.28, a P/E/G ratio of 1.12 and a beta of 0.37. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The stock has a fifty day simple moving average of $939.47 and a 200-day simple moving average of $818.98.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the previous year, the firm earned $1.18 EPS. Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is presently 29.35%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. BMO Capital Markets set a $1,200.00 target price on Eli Lilly and Company in a research note on Thursday, December 4th. Guggenheim reiterated a “buy” rating and set a $1,163.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research report on Friday, October 10th. Finally, Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,109.24.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.